Literature DB >> 11792431

Nuclear localisation of CIITA is controlled by a carboxy terminal leucine-rich repeat region.

Michael Towey1, Adrian P Kelly.   

Abstract

Regulation of both IFN-gamma inducible and constitutive MHC class II gene transcription is under the control of CIITA. This master regulator is synthesised in the cytosol and must translocate to the nucleus in order to activate class II gene transcription. Here, we demonstrate that, in a patient deficient in MHC class II gene expression, a single missense mutation results in sequestration of CIITA within the cytosol. The mutation is situated in a region that bears homology to the beta strand domain of ribonuclease inhibitor-like leucine-rich repeat (LRR) motifs. Deletion and mutagenesis analysis suggest that structural integrity of this region is required for efficient nuclear localisation. Importantly, we show that in the absence of amino terminal domains, the carboxy terminal LRR region is sufficient to efficiently target GFP chimeric proteins to the nucleus. CIITA therefore encodes multiple domains that can, in isolation, efficiently target to the nuclear compartment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792431     DOI: 10.1016/s0161-5890(01)00093-1

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  ZXDC, a novel zinc finger protein that binds CIITA and activates MHC gene transcription.

Authors:  Wafa Al-Kandari; Srikarthika Jambunathan; Vandana Navalgund; Rupa Koneni; Margot Freer; Neeta Parimi; Rajini Mudhasani; Joseph D Fontes
Journal:  Mol Immunol       Date:  2006-04-04       Impact factor: 4.407

Review 2.  Structural aspects of the MHC expression control system.

Authors:  Grady Nash; Bhaskar Paidimuddala; Liman Zhang
Journal:  Biophys Chem       Date:  2022-02-15       Impact factor: 2.352

3.  HLA Class II Antigen Processing and Presentation Pathway Components Demonstrated by Transcriptome and Protein Analyses of Islet β-Cells From Donors With Type 1 Diabetes.

Authors:  Mark A Russell; Sambra D Redick; David M Blodgett; Sarah J Richardson; Pia Leete; Lars Krogvold; Knut Dahl-Jørgensen; Rita Bottino; Marcela Brissova; Jason M Spaeth; Jenny Aurielle B Babon; Rachana Haliyur; Alvin C Powers; Chaoxing Yang; Sally C Kent; Alan G Derr; Alper Kucukural; Manuel G Garber; Noel G Morgan; David M Harlan
Journal:  Diabetes       Date:  2019-03-04       Impact factor: 9.461

4.  Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.

Authors:  Thomas Prod'homme; Benjamin Dekel; Giovanna Barbieri; Barbara Lisowska-Grospierre; Rina Katz; Dominique Charron; Catherine Alcaide-Loridan; Shimon Pollack
Journal:  Immunogenetics       Date:  2003-10-22       Impact factor: 2.846

5.  Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator.

Authors:  Lilien N Voong; Allison R Slater; Sebila Kratovac; Drew E Cressman
Journal:  J Biol Chem       Date:  2008-02-01       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.